NextCure (NXTC) Piper Sandler 37th Annual Healthcare Conference summary

Key program updates

• SIM0505, targeting CDH6, is in phase I with data expected in the first half of next year; enrollment ongoing in both China and the US, leveraging prior safety data to accelerate progress.

• LNCB74, targeting B7-H4, uses a stable beta-glucuronidase linker and is advancing to higher dose cohorts after strong safety results; data also anticipated in the first half of next year.

• Both ADCs focus initially on ovarian and endometrial cancers, with potential for broader application based on target expression.

• Combination or sequential use of ADCs is being explored, with future treatment paradigms likely to be driven by tumor expression profiling and resistance patterns.

• Pipeline includes non-oncology assets in osteogenesis imperfecta and Alzheimer's, with plans to spin these out or partner, while maintaining focus and ownership in ADCs.

Financial and strategic outlook

• Cash position is just under $50 million, sufficient to fund operations into the first half of 2027 and cover key data milestones for both lead ADC programs.

• Additional financing is planned for early next year to support advancement into phase II trials.

• Business development efforts are ongoing for non-core assets, with a strategy shift toward spinning out non-oncology programs and retaining ADC ownership.